CytoImmune Therapeutics

CytoImmune Therapeutics is a biotechnology startup with a vision to develop novel, coordinated immunotherapy solutions for patients. The company's CoalesceNT™ platform integrates bispecific antibody (biAb) and chimeric antigen receptor (CAR) technology to orchestrate an immune response with natural killer (NK) and T cells. This innovative approach expedites time-to-treatment and delivers a dynamic immune response mirroring natural immunity. Established in 2019, CytoImmune Therapeutics operates in the Biotechnology and Health and Wellness sectors, aiming to offer cutting-edge solutions in the field of immunotherapy. As of now, the company's headquarters and specific investment details are not available. CytoImmune Therapeutics' pioneering approach and focus on addressing unmet needs in immunotherapy present an intriguing prospect for potential investors in the biotech and healthcare industries.